Skip to content
Rigosertib
Rigosertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelodysplastic syndromesD009190D46763——13
AnemiaD000740EFO_0004272D64.9—12——3
Myelomonocytic leukemia chronicD015477C93.1112——3
Refractory anemia with excess of blastsD000754D46.2——2——2
Pancreatic neoplasmsD010190EFO_0003860C25——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.043———4
Squamous cell neoplasmsD01830722———3
Epidermolysis bullosa dystrophicaD016108Q81.221———2
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.021———2
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034021———2
Non-small-cell lung carcinomaD00228911———1
AdenocarcinomaD00023011———1
Squamous cell carcinoma of head and neckD000077195—1———1
Squamous cell carcinomaD002294—1———1
Esophageal squamous cell carcinomaD000077277—1———1
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C807————7
B-cell chronic lymphocytic leukemiaD015451C91.12————2
Hepatocellular carcinomaD006528C22.01————1
Head and neck neoplasmsD0062581————1
Healthy volunteers/patients—1————1
Multiple myelomaD009101C90.01————1
Mantle-cell lymphomaD020522C83.11————1
Waldenstrom macroglobulinemiaD008258C88.01————1
Hairy cell leukemiaD007943C91.41————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRIGOSERTIB
INNrigosertib
Description
Rigosertib is an N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine in which the double bond has E-configuration. It is a non-ATP-competitive inhibitor of PLK1 with an IC50 of 9 nM and exhibits anti-cancer properties. It has a role as a microtubule-destabilising agent, an EC 2.7.11.21 (polo kinase) inhibitor, an apoptosis inducer and an antineoplastic agent. It is a conjugate acid of a rigosertib(1-).
Classification
Small molecule
Drug classserine/threonine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1cc(OC)c(/C=C/S(=O)(=O)Cc2ccc(OC)c(NCC(=O)O)c2)c(OC)c1
Identifiers
PDB—
CAS-ID592542-59-1
RxCUI—
ChEMBL IDCHEMBL1241855
ChEBI ID—
PubChem CID6918736
DrugBankDB12146
UNII ID67DOW7F9GL (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Rigosertib - Onconova Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 563 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
17 adverse events reported
View more details